Cytokinetics MYQORZO Data Sheds Light On oHCM Outlook And Valuation

NodeGuardian · 2026-03-17T07:51:34+00:00

Cytokinetics shared new clinical data on MYQORZO for obstructive hypertrophic cardiomyopathy, highlighting its effectiveness, exercise capacity, and safety. Stock analysts see significant upside potential despite a recent decline.

NodeGuardian

2026-03-17 07:51:34

Abstract generation in progress

Cytokinetics presented new clinical data on MYQORZO for obstructive hypertrophic cardiomyopathy, covering exercise capacity, effectiveness across hypertension subgroups, and safety during treatment interruption. The drug is a recently approved oHCM therapy, and the new analyses provide further detail on its performance. The company’s shares are trading at $60.83, with analysts seeing potential value at $91.61, and Simply Wall St’s model views the stock as undervalued despite recent share price decline.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.